Dare Bioscience Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.13
Dividend & YieldN/A$ (N/A)
Beta 1.21
Market capitalization 76.09M
Operating cash flow -22.11M
ESG Scores unknown

Company description

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 151.49k 370.54k 483.03k 10.06M
Total Cashflows From Investing Activities -518.84k 6.14M -17.62k -14.52k
Net Borrowings 367.29k 367.29k 367.29k
Total Cash From Financing Activities 10.11M 5.15M 25.13M 75.85M
Change To Operating Activities 220.11k 537.07k 964.66k -647.33k
Issuance Of Stock 10.11M 5.15M 24.76M 75.85M
Net Income -16.74M -14.26M -27.4M -38.7M
Change In Cash -753.96k -2.03M -110.64k 47M
Effect Of Exchange Rate -78.65k -5.9k 11.24k -63.59k
Total Cash From Operating Activities -10.27M -13.32M -25.23M -28.76M
Depreciation 2.44k 11.14k 43.23k 26.41k
Change To Account Receivables 253.17k -201.42k 95.04k -685.15k
Other Cashflows From Financing Activities
Change To Netincome 5.84M 231.02k 579.86k 1.18M
Capital Expenditures -11.84k -17.62k -17.62k -14.52k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 6.41M 8.55M 20.77M 30.62M
Income Before Tax -16.74M -14.26M -27.4M -38.7M
Net Income -16.74M -14.26M -27.4M -38.7M
Selling General Administrative 4.66M 5.27M 6.55M 8.35M
Gross Profit -625k -533.33k -83.33k -100k
Ebit -11.69M -14.34M -27.4M -39.07M
Operating Income -11.69M -14.34M -27.4M -39.07M
Interest Expense
Income Tax Expense
Total Revenue
Cost Of Revenue 625k 533.33k 83.33k 100k
Total Other Income ExpenseNet -4.9M 81.05k 1.51k 372.41k
Net Income From Continuing Ops -16.74M -14.26M -27.4M -38.7M
Net Income Applicable To Common Shares -16.74M -15.05M -27.41M -38.7M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 1.1M 7M 8.7M 17.05M
Total Stockholder Equity 6.73M 440.83k -1.15M 38.75M
Other Current Liabilities 2.02M 2.56M 10.54M
Total Assets 7.83M 7.44M 7.55M 55.81M
Common Stock 1.14k 1.97k 4.16k 8.39k
Other Current Assets
Retained Earnings -28.97M -44.02M -71.43M -110.13M
Treasury Stock -96.73k -102.62k -91.39k -154.97k
Cash 6.81M 4.78M 4.67M 51.67M
Total Current Liabilities 1.09M 5.61M 7.66M 16.05M
Other Stockholder Equity -96.73k -102.62k -91.39k -154.97k
Property, Plant, and Equipment 9.4k 551.81k 277.48k 242.71k
Total Current Assets 7.24M 6.44M 6.98M 55.3M
Net Tangible Assets 6.73M 440.83k -1.15M 38.75M
Net Receivables 31.04k 555.21k 460.17k 1.15M
Accounts Payable 459.7k 1.08M 1.02M 2.1M


Insider Transactions

Here are the insider transactions of stock shares related to Dare Bioscience Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
HAWLEY ROGER LPurchase at price 1.10 per share.I2019-04-11Director454.55k
HAWLEY ROGER LPurchase at price 1.45 per share.D2018-06-11Director140k
JOHNSON SABRINA MARTUCCIStock Award(Grant) at price 0.00 per share.I2017-07-19Chief Executive Officer962.06k
HAWLEY ROGER LStock Award(Grant) at price 0.00 per share.D/I2017-07-19Director490.41k
STEELE ROBIN JOANStock Award(Grant) at price 0.00 per share.I2017-07-19Director246.17k
WALTERS-HOFFERT LISAStock Award(Grant) at price 0.00 per share.I2017-07-19Chief Financial Officer443.51k
MCKEE WILLIAM TStock Award(Grant) at price 0.77 per share.D2017-01-03Director1.95k
RASTETTER WILLIAM HStock Award(Grant) at price 0.77 per share.D2017-01-03Director24.35k
FRIEDMAN PAUL AStock Award(Grant) at price 0.77 per share.D2017-01-03Director4.87k
GUIFFRE CHRISTOPHER D TStock Award(Grant) at price 0.60 per share.D2016-12-30Chief Executive Officer5.73k
MCKEE WILLIAM TStock Award(Grant) at price 1.02 per share.D2016-10-03Director1.47k
RASTETTER WILLIAM HStock Award(Grant) at price 1.02 per share.D2016-10-03Director18.38k
FRIEDMAN PAUL AStock Award(Grant) at price 1.02 per share.D2016-10-03Director3.68k
WALT DAVID RStock Award(Grant) at price 1.02 per share.D2016-10-03Director11.27k
ARBUCKLE STUART AStock Award(Grant) at price 1.02 per share.D2016-10-03Director5.64k
GUIFFRE CHRISTOPHER D TStock Award(Grant) at price 1.80 per share.D2016-06-30Chief Executive Officer4k
WALT DAVID RPurchase at price 2.08 - 2.09 per share.D2016-02-22Director2.29k
WALT DAVID RPurchase at price 2.09 - 2.12 per share.D2016-02-18Director8.96k
WALT DAVID RPurchase at price 2.00 per share.D2016-02-16Director8.81k
WALT DAVID RPurchase at price 2.03 - 2.08 per share.D2016-02-11Director8.85k
WALT DAVID RPurchase at price 2.08 - 2.22 per share.D2016-02-09Director9k
WALT DAVID RPurchase at price 2.29 - 2.31 per share.D2016-02-05Director8.56k
WALT DAVID RPurchase at price 2.27 - 2.37 per share.D2016-02-03Director8.41k
WALT DAVID RPurchase at price 2.37 - 2.41 per share.D2016-02-01Director5.7k
WALT DAVID RPurchase at price 2.45 - 2.47 per share.D2016-01-28Director9k
WALT DAVID RPurchase at price 2.35 - 2.44 per share.D2016-01-26Director8.8k
WALT DAVID RPurchase at price 2.24 - 2.32 per share.D2016-01-22Director9k
WALT DAVID RPurchase at price 2.35 - 2.52 per share.D2016-01-20Director8.9k
WALT DAVID RPurchase at price 2.42 - 2.64 per share.D2016-01-15Director8.57k
WALT DAVID RPurchase at price 2.69 - 2.89 per share.D2016-01-13Director8.68k
WALT DAVID RPurchase at price 2.86 - 2.87 per share.D2016-01-11Director8.86k
WALT DAVID RPurchase at price 2.87 - 3.03 per share.D2016-01-07Director8.8k
WALT DAVID RPurchase at price 3.01 - 3.06 per share.D2016-01-05Director8.8k
O NEILL JAMES EStock Award(Grant) at price 2.38 per share.D2015-12-31Officer1.1k
GUIFFRE CHRISTOPHER D TStock Award(Grant) at price 2.38 per share.D2015-12-31Chief Executive Officer2.76k
WALT DAVID RPurchase at price 3.75 per share.D2015-12-03Director10k
WALT DAVID RPurchase at price 3.25 per share.D2015-11-30Director5.37k
WALT DAVID RPurchase at price 3.28 - 3.37 per share.D2015-11-27Director12.12k
CVF L L CPurchase at price 6.00 per share.D2015-04-07Beneficial Owner of more than 10% of a Class of Security333.33k
FETZER OLIVER STEFFENConversion of Exercise of derivative security at price 3.34 per share.D2014-05-16Chief Executive Officer30k
RASTETTER WILLIAM HPurchase at price 7.00 per share.I2014-04-15Director18.87k
RASTETTER WILLIAM HConversion of Exercise of derivative security at price 0.00 per share.D2014-04-15Director41.44k
ELI LILLY & COPurchase at price 7.00 per share.I2014-04-15Beneficial Owner of more than 10% of a Class of Security733.45k
ELI LILLY & COConversion of Exercise of derivative security at price 0.00 - 7.00 per share.I2014-04-15Beneficial Owner of more than 10% of a Class of Security1.62M
CVF L L CPurchase at price 7.00 per share.D2014-04-15Beneficial Owner of more than 10% of a Class of Security827.46k
CVF L L CConversion of Exercise of derivative security at price 0.00 per share.D2014-04-15Beneficial Owner of more than 10% of a Class of Security1.43M
CRANE ALAN LPurchase at price 7.00 per share.I2014-04-15Director and Beneficial Owner of more than 10% of a Class of Security1.47M
CRANE ALAN LConversion of Exercise of derivative security at price 0.00 - 7.00 per share.I2014-04-15Director and Beneficial Owner of more than 10% of a Class of Security3.22M
POLARIS VENTURE MANAGEMENT CO IV L L CConversion of Exercise of derivative security at price 0.00 per share.I2014-04-15Beneficial Owner of more than 10% of a Class of Security1.43M
POLARIS VENTURE MANAGEMENT CO V L L CPurchase at price 6.56 per share.I2014-04-15Beneficial Owner of more than 10% of a Class of Security1.47M
POLARIS VENTURE MANAGEMENT CO V L L CConversion of Exercise of derivative security at price 0.00 per share.I2014-04-15Beneficial Owner of more than 10% of a Class of Security1.79M

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Dare Bioscience Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Dare Bioscience Inc

Here is the result of two systematic investment strategies applied to Dare Bioscience Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Dare Bioscience Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Dare Bioscience Inc:

Dare Bioscience Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 60.74% on the backtest period.

Performance at glance

Performance

60.74 %

Latent gain

1062.9 $

Invested capital

1749.9 $

Annualized return

14.81 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Dare Bioscience Inc

This is the result of two momentum investment strategies applied to Dare Bioscience Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Dare Bioscience Inc

The following chart shows all the entries opened by the momentum investment system on Dare Bioscience Inc:

Dare Bioscience Inc momentum entries
  • The first momentum investment strategy would give 61.99% of return on Dare Bioscience Inc. That represents 3409.9$ of latent gain with 5500.5$ of employed capital.
  • The second momentum investment strategy would give 66.78% of return on Dare Bioscience Inc. That represents 2171.21$ of latent gain with 3251.19$ of employed capital.
Performance at glance (1Q Momentum)

Performance

61.99 %

Latent gain

3409.9 $

Invested capital

5500.5 $

Annualized return

25.64 %
Performance at glance (2Q Momentum)

Performance

66.78 %

Latent gain

2171.21 $

Invested capital

3251.19 $

Annualized return

18.45 %

Momentum equity curve on Dare Bioscience Inc

The following chart shows the equity curve of the two momentum strategies applied to Dare Bioscience Inc:

Dare Bioscience Inc momentum equity

Note: the dividends potentially given by Dare Bioscience Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Dare Bioscience Inc

The following chart shows the employed capital evolution of the two momentum strategies on Dare Bioscience Inc since the beginning:

Dare Bioscience Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Dare Bioscience Inc

Buy the dip entry openings on Dare Bioscience Inc

Dare Bioscience Inc

The performance achieved by the robo-advisor on Dare Bioscience Inc is 53.85%. That represents 134.4$ of latent gain with 249.6$ of employed capital. The following chart shows Dare Bioscience Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Dare Bioscience Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

53.85 %

Latent gain

134.4 $

Invested capital

249.6 $

Annualized return

25.64 %

Equity curve of the strategy applied to Dare Bioscience Inc

The following chart shows the result of the investment strategy applied to Dare Bioscience Inc:

Dare Bioscience Inc

Note: the dividends potentially given by Dare Bioscience Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Dare Bioscience Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Dare Bioscience Inc:

Dare Bioscience Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Dare Bioscience Inc

In this section, I will compare the three previous investment strategies applied to Dare Bioscience Inc.

Equity curve comparison on Dare Bioscience Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Dare Bioscience Inc investment strategy comparison

Employed capital comparison on Dare Bioscience Inc

Dare Bioscience Inc investment comparison

Performance comparison on Dare Bioscience Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 60.74% 1062.9$ 1749.9$ 14.81%
Momentum 1 quarter 61.99% 3409.9$ 5500.5$ 16.06%
Momentum 2 quarters 66.78% 2171.21$ 3251.19$ 18.45%
Non-directional 53.85% 134.4$ 249.6$ 25.64%
Annualized return comparison

Automatic investment

14.81 %

Momentum 1Q

18.45 %

Momentum 2Q

18.45 %

Non-directional

25.64 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Dare Bioscience Inc:

Positive correlations

Most correlated stocks this year

  • Dare Bioscience Inc

  • Most correlated stocks last 3 months

  • First Community Corp
  • Global Ship Lease Inc - Class A
  • Dare Bioscience Inc
  • MS CONCEPT

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Dare Bioscience Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Dare Bioscience Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Dare Bioscience Inc
    Country United States
    City San Diego
    Address 3655 Nobel Drive
    Phone 858 926 7655
    Website www.darebioscience.com
    FullTime employees 20
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker DARE
    Market www.nasdaq.com

    Dare Bioscience Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown